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Mesenchymal stem cells (MSCs) are a promising source for cell therapy due to their pluripotency and immunomodulant
proprieties. As the identification of “optimal” conditions is important to identify a standard procedure for clinical use. Percoll,
Ficoll and whole bone marrow directly plated were tested from the same sample as separation methods. The cells were seeded at
the following densities: 100 000, 10 000, 1000, 100, 10 cells/cm2. After reaching confluence, the cells were detached, pooled and
re-plated at 1000, 500, 100, and 10 cells/cm2. Statistical analyses were performed. Cumulative Population Doublings (PD) did
not show significant differences for the separation methods and seeding densities but only for the plating density. Some small
quantity samples plated in T25 flasks at plating densities of 10 and 100 cells/cm2 did not produce any expansion. However, directly
plated whole bone marrow resulted in a more advantageous method in terms of CFU-F number, cellular growth and minimal
manipulation. No differences were observed in terms of gross morphology, differentiation potential or immunophenotype. These
data suggest that plating whole bone marrow at a low cellular density may represent a good procedure for MSC expansion for
clinical use.
1. Introduction
In recent years, a large number of studies have shown
that mesenchymal stem cells (MSCs) represent an attractive
option for new therapeutic approaches, due to their plasticity
and differentiative potential. MSCs aremultipotent stem cells
that are able to differentiate into different lineages including
mesodermal, ectodermal, and endodermal type cells [1–4].
MSCs can be easily isolated by their ability to adhere to
plastic generating single-cell-derived colonies [5, 6] that can
be expanded to obtain high numbers of cells for clinical use
in cell and gene therapy for a number of human diseases [1].
Several methods have been described for isolating MSCs
from bone marrow (BM), including the use of immuno-
magnetic beads, density gradient separation, and direct BM
plating [2, 7–11]. Density gradients such as Ficoll or Percoll
centrifugation are commonly used to isolate MSCs from
human BM [2, 8, 11, 12] whereas direct plating is commonly
used for cells from rats [10], mice [13], and rabbits [14]
which have limited available BM. Hemopoietic contamina-
tion, due to the presence of macrophages, endothelial cells,
and lymphocytes which also adhere to plastic, is often present
in the early BM monolayer [2, 15]. However, only fibroblast-
like spindle-shaped cells proliferate and form colonies
termed colony forming unit-fibroblasts (CFU-Fs) which are
representative of the more highly proliferative cells in MSCs
[6, 16]. On the basis of isolation and expansion protocols,
the CFU-Fs originate MSCs with different proliferative and
differentiative potentials which may be either subtle or
significant [9, 17]. The International Society for Cellular
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Therapy proposed three minimal criteria to identify MSCs
(an abbreviation used to indicate multipotent mesenchymal
stromal cell): (1) the adherence to plastic; (2) the specific
surface antigen expression (positivity for CD105, CD73,
CD90 and the lack of expression of CD45, CD34, CD14 or
CD11b, CD79a or CD19 and HLA class II; (3) the multi-
potent capacity to differentiate into osteoblasts, adipocytes,
and chondrocytes under standard in vitro differentiating
conditions [18].
The safety, feasibility, and efficiency of MSC transplanta-
tion for clinical use are currently the object of studies, and, as
several protocols use extremely high numbers of MSC (until
109), the identification of “optimal” conditions for in vitro
cell culture should also be investigated.
Isolation methods, including medium, plastic, seeding
density, growth factors, and chemicals, influence the expan-
sion, differentiation, and immunogenic properties of MSCs.
Futhermore, donor age and disease stage [19, 20] can also
influence MSC yield, proliferation rate, and differentiation
potential. BM MSCs are usually isolated from BM mononu-
clear cells obtained after gradient separation and for their
capacity to adhere to plastic.
Percoll, a suspension of colloidal silica particles, widely
used at different densities to separate cells, organelles, viruses
and other subcellular particles, or Ficoll a polymer of
sucrose, traditionally used to separate mononuclear cells and
lymphocytes, have both been used at densities of 1.073 g/mL
[2, 21–23] and 1.077 g/mL [24–26], respectively, to isolate
MSCs with high proliferative and differentiative potential.
In this study, using the same BM sample, we isolated
MSCs from healthy donors using different separation and
expansion methods. We used Ficoll, Percoll, and direct BM
plating as the separatingmethods and tested different seeding
and plating cellular densities to verify the best method to
obtain a high number of MSCs for clinical use.
2. Material and Methods
2.1. Harvest and Preparation of MSCs. Bone marrow (BM)
cells were harvested from the iliac crest of adult or pediatric
Caucasian donors who underwent bone marrow collection
for a related patient after informed consent. When available,
we also used an unfiltered bone marrow collection bag (Bax-
ter Healthcare Corporation, IL, USA) which was normally
discarded before the BM infusion. The bag was washed
3 times with Phosphate Buffer Saline (PBS) 1X (Lonza,
Verviers, Belgium), and the cells were collected at 200 g
for 10 minutes. An aliquot of whole BM was counted and
plated directly in MSC Medium (Lonza, Verviers, Belgium)
containing 10% Foetal Bovine Serum (FBS) at the various
densities in T25 o T75 flasks (Becton Dickinson, Franklin
Lakes, NJ, USA). The remaining part of the BM sample
was divided into 2 parts for the Percoll and Ficoll gradient
separation. The cells were layered on a Percoll (Sigma
Aldrich, St. Louis, MO, USA) gradient (1.073 g/mL density)
according to a previously reported method [20] and on a
Ficoll (Biochrom, Milton Road, Cambridge, UK) gradient
(1.077 g/mL density). The cells were centrifuged at 1100 g for
30minutes, and 400 g for 30minutes respectively. The cells in
the interphase were recuperated, washed twice with PBS 1X
(200 g for 10 minutes), seeded in a MSC Medium containing
10% FBS and maintained at 37◦C with an atmosphere of 5%
CO2 at the following densities: 100 000, 10 000, 1000, 100,
and 10 cells/cm2. After 5 days, the nonadherent cells were
removed and refed every 3-4 days and when they reached
confluence, they were detached, pooled, and replated for a
further 3–5 passages at 1000, 500, 100, and 10 cells/cm2.
2.2. MSC Analysis. The cells were counted and analyzed at
each passage for cellular growth, viability and immunophe-
notype by cytofluorimetric analysis.
2.3. MSC Clonogenic and Proliferation Potential. The clono-
genic potential of isolated MSCs from the 3 different BM
fractions (whole BM, mononuclear cell [MNC] fraction
after Ficoll and Percoll gradient) were tested by fibroblastic-
colony-forming unit (CFU-F) assay. The cells were seeded
at the different densities, and the medium changed every
3-4 days. MSC clonogenic precursors (CFU-F) were scored
macroscopically after 2 weeks, and clusters of more than
50 cells were considered colonies. All the experiments were
performed in duplicate.
On average, the CFU-Fs were counted by 2 different
operators. The CFU-Fs were indicated as the fibroblastic
clones obtained from the starting cellular compartment of
the whole BM.
The cellular expansion growth rate of MSCs was eval-
uated by cell count in a Burker Chamber at each passage
and expressed in terms of population doubling (PD) using
the formula logN/ log 2, where N is the cell number of the
confluent monolayer divided by the initial number of cells
seeded [20].
2.4. Cytofluorimetric Analysis of MSCs. The identification of
adherent cells was performed by flow cytometry analysis.
At each passage, 200 000–500 000 cells were stained for 20
minutes with anti CD105 PE (Immunostep S.L, Salamanca,
Spain), CD45 FITC, CD14 PE, CD73 PE, CD44 PE, CD29
FITC (Becton Dickinson, San Jose, CA, USA), CD105 PE,
CD166 FITC, CD90 FITC, CD106 PE (Beckman Coulter,
Brea, CA, USA.). The labeled cells were thoroughly washed
with PBS 1X and analyzed on a FACScanto II (Becton
Dickinson) with the DIVA software program. The percentage
of positive cells was calculated using the cells stained with Ig
FITC/PE as a negative control.
2.5. Differentiation Potential Assay. For differentiation exper-
iments, from the 1st to the 5th passages MSCs were cul-
tured in osteogenic, adipogenic and chondrogenic medium
(Lonza) according to themanufacturer’s instructions. Briefly,
20 000 and 50 000 cells were plated in a T-25 flask for
osteogenesis and adipogenic culture conditions, respectively,
allowing the cells to adhere to the culture surface for 24
hours in MSC medium (Lonza). To induce osteogenesis and
adipogenesis, the medium was replaced with specific com-
plete induction medium (Lonza). After 21 days, osteogenic
differentiation was demonstrated by the accumulation of
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calcium (crystalline hydroxyapatite detection by Von Kossa
staining) in separated cells plated in chamber slides in the
same culture conditions.
For the adipogenic differentiation, adipogenic induction
and maintenance medium were alternatively used every 3-
4 days, and the presence of intracellular lipid vesicles visible
after 2-3 weeks’ culture was assessed by Oil Red O staining.
For chondrogenic differentiation, an aliquot of 250 000
cells was washed twice with incomplete chondrogenic
medium (Lonza) in 15mL polypropylene culture tubes.
Finally, the cells were resuspended in complete chondrogenic
medium, centrifuged and, without aspirating thesurnatant,
the tubes were incubated at 37◦C in a humidified atmosphere
of 5% CO2. Chondrogenic differentiation was due to the
growth of the cells as cellular aggregates floating freely
in suspension culture with Transforming Growth Factor
(TGF)-beta3. The pellet was included in paraffin and stained
with Alcian Blue to identify the presence of hyaluronic acid
and sialomucin.
2.6. Telomere Length (TL) Evaluation. TL evaluation was
carried out by Southern Blot (SB) analysis as described
elsewhere [27]. Briefly, 22 µg of DNAwere digested bymixing
HinfI (20U) and RsaI (20U) (Roche Diagnostic, Mannheim,
Germany) and incubating at 37 for 2 h (Figure 5). Resulting
DNA fragments were then separated on a 0.8% agarose gel by
electrophoresis in 1X TAE running buffer and 5 µL of ethid-
ium bromide. Separated DNA was subsequently transferred
to a positively charged nylon membrane (RocheDiagnostic
Mannheim, Germany). After an overnight transfer, in order
to fix DNA fragments the membrane was exposed to UV
light for 10 minutes. Hybridization was carried out with the
TeloTAGG Telomere Length Assay Kit (Roche Diagnostics,
Manheim, Germany).
Membranes were submerged in a prehybridization solu-
tion and then incubated in the hybridization solution (2 µL
of the digoxigenin (DIG)-labeled telomere-specific probe
added to the prehybridization solution) for 3 h at 62◦C.
Then, membranes with DNA fragments linked to telomere
probes were incubated with a digoxigenin-specific antibody
covalently coupled to alkaline phosphatase (AP).
The results were visualized using AP metabolizing CDP-
Star, a highly sensitive chemiluminescent substrate.
The light signal was recorded on X-ray film (Lumi-
Film Chemiluminescent Detection Film, Roche Diagnostic,
Mannheim, Germany) and scanned for analysis.
Median TR length was calculated using the software
quantity One by Biorad (Hemel Hempstead, UK).
2.7. Statistical Analysis. Cell growth data were analyzed by
SPSS 15 for Windows (SPSS Inc, Chicago, IL). The results
were expressed as medians and ranges. The differences
between paired samples were evaluated by Friedman’s test
[28, 29] and a post hoc multiple comparison analysis using
the Least Significant Difference (LSD) method.
All statistical tests were two-sided and significant for a P
value <0.05.
3. Results
3.1. MSC Harvest and Preparation. Ten bone marrow sam-
ples were collected from donors: 3 over 18 years of age
(age range: 39–50 years) (2 male and 1 female) and 7 (all
male) with ages younger than 18 years (age range: 0.5–10
years). The study was conducted according to the Helsinki
Declaration. The whole BM was counted and seeded for
all the experiments; the remaining part of the sample was
separated into equal fractions for MSC separation by Ficoll
and Percoll, respectively. The median of initial cell numbers
for gradient separation was 69 × 106 (range: 21–82 ×
106) and, after separation, the total recovery corresponded
to 13.5% and 15.7%, respectively after Ficoll and Percoll
(median value; range Ficoll: 5.0–18.9%, Percoll: 1.0–28.8%).
These data showed that there were no differences between
Ficoll and Percoll in terms of cell count and recovery after
isolation.
3.2. MSC Isolation. Adherent cells were observed in all the
samples after 3–5 days’ culture and in the following 2
weeks an adherent monolayer was achieved. The BM cells
rapidly generated a confluent layer of cells with an elongated,
fibroblastic shape. The viability at each passage was always
over 98%. No morphological differences were observed on
the MSCs isolated from whole BM, Ficoll and Percoll,
but when early passage cells were compared with late
passage cells, MSCs showed a different morphology. The cells
increased in size and showed a polygonal morphology with
evident filaments in the cytoplasm especially when isolated
from the adult donors.
3.3. MSC Analysis. MSCs isolated from healthy donors were
analyzed for the first 3 passages with a median interval
between one passage and the next of 16 days (range: 7–40).
We observed heterogeneous MSC preparation and a distinct
population of spindle-shaped or flat MSCs in the flasks,
although no morphological differences were observed in
the 3 preparations (Ficoll, Percoll, and whole BM). Figure 1
shows the clones from different methods after 10 days from
seeding at the various densities. In 7 out of 10 cultures we
did not observe clones in culture seedings at 10 and 100 cells.
Interestingly, we observed clones at lower densities only in
the 3 samples obtained from the washout of discarded BM
collection bags and filters. In addition, these samples were
obtained from child patients.
After detachment, the cells replated at 1000, 500, 100,
and 10 cells/cm2 formed clones that reached confluence in
a median of 16 days (range: 7–40). The cells pooled and
replated at the second and third passages also formed clones
in all preparations. Figure 2 shows the clones at the second
passage after 7 days from plating.
In order to compare the effect of 3 different separation
methods and different densities on the proliferative capacity
of MSCs, 3 BM samples were plated to ascertain the
CFU-F frequency. The CFU-F number was calculated in
relation to the initial cell number in the BM sample and
by comparing the 3 separation methods. The results were
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Figure 1: Phenotype of different clones observed after Percoll and Ficoll gradient separation and whole BM 10 days from seeding at different
densities.
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Figure 2: Phenotype of different clones observed after Percoll and Ficoll gradient separation and whole BM 7 days from plating.
as follows: whole BM showed a median of 104.4 CFU-
F (range: 7.2–179.7) per 106 cells; after Ficoll and Percoll
separation, BM showed a median of 3.8 (range: 2.7–49.8)
and 0.1 (range: 0–16.4) CFU-F per 106. We observed no
direct correlation between the number of cells plated and
the number of CFU-Fs counted when analyzing the effect
of the densities. In particular, at seedings of 10, 100, 1000,
10 000, and 100 000 cells/cm2, we observed a median of 0
(range: 0-0), 0 (range: 0.0–44.4); 6.2 (range: 0.7–104.0);
62.5 (7.4–111.7) and 11.3 (3.1–13.8), respectively. Significant
differences were noted among seedings at 10 with 10 000
and 100 000 cells/cm2 between 100 with 10 000 cells/cm2 and
1 000 with 10 000. The analysis of the 3 different separation
methods and the different seeding densities, considering the
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grand total of all values obtained for whole BM, Ficoll and
Percoll (N = 10), as shown in Table 1(a), and the grand
total of all values of each density, as shown in Table 1(b), did
not show significantly different growth rate values at the first
passage (P = 0.49 and P = 0.51, resp.).
On 4 samples, it was possible to perform a complete
analysis for cumulative PD from the 1st to the 3rd passages,
and the results showed that BM always showed a more
advantageous growth compared to Ficoll and Percoll separa-
tion even though the statistic analysis showed no significant
differences (P = 0.653; P = 0.931 and P = 0.528 at the 1st,
2nd and 3rd passages, resp.).
As we did not observe MSC clones in more than half of
the primary cultures for the seeding at 10 and 100 cells/cm2,
these densities were excluded for the final analysis. At the
1st passage, we observed a significant statistical difference
between the seedings at 1000 and 10 000 (P = 0.028), but
not between 10 000 and 100 000 cells/cm2.
The analysis on the effect of plating density at 10, 100,
500, and 1000 cells/cm2 at the 1st, 2nd, and 3rd passages is
summarized in Table 3. In particular, we observed significant
statistical differences at the 2nd passage between plating at 10
compared to 500 and 1000 cells/cm2 at both the 2nd and 3rd
passages (P = 0.001 and P = 0.017).
3.4. Viability Evaluation. Trypan blue staining analysis
showed a viability of between 98%–100% in all the analyzed
samples with no differences between the two groups. The
same results were confirmed after 7AAD staining in the
cytofluorimetric analysis.
3.5. Immunophenotype Analysis by Flow Cytometry. During
the 1st 3 passages, the cells were analyzed at each passage
for the expression of CD45 and CD14, haematopoietic
surface antigens; CD90; CD29, CD44; CD105; CD166 and
CD106, CD73. At the 1st passage, MSCs isolated from whole
BM were CD45, CD14 negative with an antigen expression
less than 5% (the median was 3.0% with a range of 0.0–
6.5% and 3.5% with a range of 0.0–7.0%, resp.), while
they showed a high expression of CD90 (median of 90.0%,
range: 65.0–93.5%), CD29 (median of 78%, range: 61.0–
97.0%), CD44 (median of 83.0%, range: 65.0–99.0%) and
CD105 (median of 90.0%, range: 65.0–95.0%) and a lower
expression of CD106, CD166 adhesion molecules (median
of 63% with a range of 2.4–88.0% and 54% with a range
of 53.0–96.0%, resp.). In the MSC isolated from Ficoll and
Percoll, at the 1st passage the immunophenotype showed
a weak hematopoietic contamination because the median
expression of CD45 was 7.5% (range: 0.0–48.0%) and 6.0%
(range: 1.0–44%:), respectively, and because the expression
for CD14 was 5.0% (range: 0.0–35%) and 4.0% (range:
0.0–24%), respectively, for the Ficoll and Percoll separation
methods. High levels of CD90, CD29, CD44, and CD105
with values over 80% and variable percentages of CD106 and
CD166 were observed without significant differences even
in the cells separated by Ficoll and Percoll. In Figure 3, the
median antigen expression which was analyzed at the 1st
passage on the cells isolated by 3 different methods (a pool of
Figure 3: Immunophenotype analysis ofMSCs isolated after Percoll
and Ficoll gradient separation and whole BM at the 1st passage.
the different seeding densities) is represented as a histogram.
During the expansion time, the MSCs were negative for the
hemopoietic antigen, whereas at each passage they expressed
high percentages of CD90, CD73, CD29, CD44, and CD105
positive cells with the median antigen expression being over
80%.
3.6. Differentiation Potential Assay. All samples induced
into differentiation with specific medium showed a multi-
potential capacity because all the MSCs, independently of
the separation methods and seeding and plating densities,
differentiated into osteoblasts, adipocytes, and chondrocytes
as shown in Figure 4. In 2 cultures of MSCs isolated from
whole BM at the 1st passage, we observed the spontaneous
presence of some clones of adipogenic and osteoblastic cells,
respectively (data not shown).
3.7. Telomere Length Analysis. We analyzed 9 samples har-
vested from pediatric healthy donors of BM (male and
female); the MSCs used for this analysis were all at the 3rd
seeding passage and were obtained by Ficoll (N = 3), Percoll
(N = 3), and direct whole BM plating (N = 3).
We observed a median of 11543 pb (range: 12181–
11504 pb), 12906 (range: 13406–12016), and 10725 pb
(range: 12060–10578 pb), respectively, for the percoll, whole
BM, and Ficoll group.
4. Discussion
In recent years, a number of insights into MSC biology, as
well as their immune regulatory proprieties and regenerative
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Table 1: Analyses of separation methods and different density effects on seeding.
(a) Analysis of different density effects on seeding (first passage).
N = 10 Whole BM Ficoll Percoll
Median 8.56 1.76 .69
Minim .12 .16 .00
Maxim 419.23 111.18 433.26
(b) Analysis of different density effects on seeding (first passage).
N = 10 10 cells/cm2 100 cells/cm2 1000 cells/cm2 10 000 cells/cm2 100 000 cells/cm2
Median .00 2.33 2.66 1.64 .41
Minim .00 .00 .00 .20 .14
Maxim 531.34 205.20 29.12 5.96 5.52
Adipocytes
(ORO staining)
Percoll Ficoll Whole BM
Osteoblasts
(Van Kossa staining)
Chondrocytes
(Alcian Blue)
20 µm20 µm
20 µm20 µm
Figure 4: Differentiation of MSCs isolated after Percoll and Ficoll gradient separation and whole BM at the 3rd passage.
potential, have provided support for considering MSCs
as a good candidate for cellular therapy for regenerative
medicine, cancer gene therapy, and the treatment of immu-
nologic diseases.
Although the culture of MSCs has been studied for over
30 years, standard criteria to isolate and characterize these
multipotent stem cells have yet to be developed.
Several methods have been described to enrich BM
MSCs for clinical applications. In this study, we tested,
from the same BM sample, 3 different isolation methods
and several different seeding and plating cellular densities.
We analyzed the cellular growth, the number of CFU-Fs,
the immunophenotype and differentiative potential in all
isolated cultures to ascertain the optimal culture condition
to isolate and expand MSCs for clinical applications.
MSCs isolated by their adherence to plastic culture
surfaces have characteristic properties that have been well
defined by a number of investigators [6, 30]. It is therefore
difficult to compare data from different laboratories for both
the different isolation and expansion methods and for the
high variability of the cells inside the culture. It is often
possible to note that in the cultures two morphologically
distinct cells are present [6, 30, 31]: Type I cells that are
spindle shaped and grow rapidly, and Type II cells that
are broad and grow slowly. Moreover, in our experiments,
we observed that the greater the number of passages, the
higher the increase in Type II cell numbers. We also observed
cells with intermediate morphologies. Other authors also
demonstrated that samples of human MSCs obtained from
iliac crest aspirates varied widely in their expandability in
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Table 2: Analyses of separation method effects on seeding in terms
of cumulative PD.
1st passage
N = 4 (P = 0.653) Whole BM Ficoll Percoll
Median 3.11 3.12 2.62
Minim 1.99 .56 1.92
Maxim 5.53 3.89 3.84
2nd passage
N = 4 (P = 0.931) Whole BM Ficoll Percoll
Median 4.55 2.68 5.88
Minim 11.41 7.62 8.00
Maxim 6.67 7.16 6.47
3rd passage
N = 4 (P = 0.528) Whole BM Ficoll Percoll
Median 10.13 10.50 8.81
Minim 8.60 5.07 8.03
Maxim 15.66 11.11 12.14
culture [32]. The variation was not explained by either the
gender or the age of the donors, nor was it explained by
the number of nucleated cells in the sample, but apparently
reflected a sampling variation in marrow aspirates from
the iliac crest, since the variation was seen between two
samples taken from the same volunteer at the same time
[32]. MSCs arise from the complex architectural structures
of perivascular cells that incompletely separate the marrow
from capillaries [30], and the yield ofMSCs apparently varies
with the presence of such architectural structures in the
aspirate site.
We observed no significant differences for the separa-
tion methods because MSCs isolated from Percoll, Ficoll,
or whole BM showed significant differences in terms of
morphology, growth rate at the 1st passage, cumulative
PD, immunophenotype and differentiative potential. The
descriptive analysis, however, showed major cellular growth
in terms of absolute values and a minor hematopoietic
contamination at the 1st passage with whole BM rather than
with Percoll or Ficoll.
As the expandability of the MSC culture might be
predictable, not from the initial growth rates in the 1st or 2nd
passages, but on the basis of the assays for CFUs [6, 25, 33],
we performed the CFU-F assays to compare the effect of
3 different separation methods in different cellular seeding
densities. Considering the initial cell number in the BM
sample, we obtained a much higher number of CFU-F in
whole BM conditions rather than after gradient separation.
Moreover, it was interesting to note that the telomere
length on MSCs isolated from whole BM was longer than
MSCs isolated from Percoll and Ficoll methods. Thus, by
cultivating the cells from whole BM we probably isolated
more immature MSCs. This latter aspect is worthy of further
research.
Even though MSC isolation and expansion by GMP
manufactured gradient media have recently been reported
(1) Ficoll
(2) Whole BM
(3) Percoll
1 2 3
Figure 5: Telomere Restriction Fragment (TRF) measurement by
Southern Blot analysis in one representative experiment on cells
isolated after Percoll and Ficoll gradient separation and whole BM
at the 3rd passage.
[34], this study confirmed that directly plated BM offers
a more advantageous method in terms of CFU-F number,
minimal manipulation, hematopoietic contamination, and
cellular growth (descriptive analysis). Our results (as has also
recently been described by Capelli et al. [35] and Lucchini et
al. [36]) show that whole BM separationmethods represent a
good procedure forMSC expansion for clinical use compared
to MSCs obtained by gradient separation. To standardize a
method of isolation and expansion, the most suitable cellular
condition should be used for all samples. We therefore
excluded seeding at 10 and 100 cells/cm2, since we observed
MSC clones in less than half of the primary cultures, whereas,
at the 1st passage, we observed a significant statistical
difference between the seedings at 1000 and 10 000, but not
between 10 000 and 100 000 cells/cm2. The CFU-F count was
significantly higher at 10 000 cells/cm2, therefore the use of
this seeding density might prove to be themost advantageous
condition. At this seeding density, a 10mL BM sample, which
contains approximately 100 million WBC, would require
10 000 cm2 or 16 T630 cm2 Cell Factories (flasks used for
large scale cell culture). The time to confluence of these
cultures would be 2 to 6 weeks which would require only
media changes and might offer, at the first passage, the
availability of cellular products (about 160 million cells) for
clinical use. The procedure proposed would provide a high
number of cells starting from a small quantity of BM. A
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Table 3: Analyses of seeding density effects in terms of cumulative PD.
1st passage
N = 4 (P = 0.068) 10 cells/cm2 100 cells/cm2 500 cells/cm2 1000 cells/cm2
Median 5.28 3.27 2.08 2.28
Minim 2.49 .68 .58 1.39
Maxim 5.57 4.65 3.07 2.63
2nd passage
N = 4 (P = 0.001)∗ 10 cells/cm2 100 cells/cm2 500 cells/cm2 1000 cells/cm2
Median 10.45 6.82 4.48 4.48
Minim 8.33 4.76 2.90 2.88
Maxim 12.06 10.15 6.99 5.94
3rd passage
N = 4 (P = 0.017)∗ 10 cells/cm2 100 cells/cm2 500 cells/cm2 1000 cells/cm2
Median 14.85 9.89 8.14 6.37
Minim 13.41 6.78 3.82 4.92
Maxim 18.78 13.69 9.84 8.52
patient would therefore only undergo a BM biopsy and not
an invasive procedure such as BM collection.
The results on cellular growth in terms of cumulative
PD confirmed other authors’ data that a low plating density
results in higher yields and a faster expansion of MSCs
[6, 19, 24, 33, 37]. We observed that small spindle-shaped
cells in some cultures grew more rapidly at a low plating
density. If however, MSCs isolated at the 1st passage were
mostly broad and uneven, the expansion was slower and
the cells were senescent at a low plating density. An other
aspect ofMSC in vitro aging was observed when the cells were
plated at lower densities (10,100) after 4-5 passages (data not
shown).
Moreover, we observed clones at lower densities only in
the 3 samples obtained from the washout of discarded bone
marrow collection bags and filters. These results confirmed
those explained by Capelli et al., that is, filtration results in
preferential trapping in the filters of hMSC precursors with
good proliferative potential, with the consequent enrichment
of these cells in the washouts compared with BM.
In conclusion, we observed that, in agreement with
other groups with wide experience in this field, [33, 38–
40], MSC populations have a diverse repertoire of distinct
subpopulations, whose proliferative, immunological, and
biological proprieties remain indeterminate. Phinney [40]
demonstrated the biochemical heterogeneity of these sub-
populations, rather than their stem-like character, contribute
more significantly to the therapeutic potential of MSCs.
To our knowledge, this is the first comparative study of
different isolation and expansion methods with or without
gradient separation. Therefore, the plating of whole BM at
a low cellular density may represent a more advantageous
procedure for MSC expansion for clinical use compared to
MSCs obtained by gradient separation.
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